Novoheart is proud to announce today that it has appointed Bernard Fermini, Ph.D. as Chief Research & Development Officer. Dr. Fermini has been a leading figure and expert in cardiac safety pharmacology for over two decades, having led research in the area at Pfizer during his 17-year tenure, where he held positions of increasing responsibilities including Co-chair of the Global Safety Pharmacology Department. He began collaborating with the Novoheart team while at Pfizer, and will be bringing his substantial expertise in safety pharmacology to complement Novoheart’s scientific team’s strengths in stem cell and tissue engineering. As a key opinion leader, Dr. Fermini will lead Novoheart’s industrial expansion in drug discovery and development, leveraging his extensive experience and networks in the pharma industry.
For more detailed press release, please click here.